International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 18s, 2025
https://www.theaspd.com/ijes.php

Dopamine and Serotonin Pathways in Balance: Mechanistic Insights and Botanical Modulation via Elaeocarpus ganitrus

Jyotsana Maurya[1*], Ridhima Kaul[2], Manoj Nazir[3]
[1*]Research Assistant, Rudraksha Project, Dharamshala, H.P, Jyotsanamaurya27@gmail.com
[2]Center for Molecular Biology, Central University of Jammu and Research Assistant, Rudraksha Project, Dharamshala, H.P, ridhimakaul9@gmail.com
[3]Associate Director, Rudraksha Project, Dharamshala, H.P, editorcorm@gmail.com

Abstract
Dopamine and serotonin are key monoaminergic neurotransmitters involved in regulating motor function, mood, cognition, and neuroendocrine activity. Imbalances in these neurotransmitter systems are implicated in a wide range of neuropsychiatric and neurodegenerative disorders, including Parkinson's disease, major depressive disorder, anxiety, schizophrenia, and bipolar disorder. While conventional pharmacological agents such as L-DOPA, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase (MAO) inhibitors have demonstrated clinical efficacy, their long-term use is often limited by adverse effects, neurotoxicity, receptor desensitization, and poor compliance. This review presents a detailed mechanistic overview of dopamine and serotonin biosynthesis, feedback regulation, and physiological interplay, while highlighting the neuromodulatory role of *Elaeocarpus ganitrus*—a medicinal plant traditionally used in Ayurvedic medicine. Phytochemical constituents of *E. ganitrus*, including quercetin, gallic acid, and rudrakine, exert multimodal actions such as MAO-A/B inhibition, antioxidant neuroprotection, and promotion of monoamine synthesis. Preclinical studies have demonstrated its effectiveness in restoring monoaminergic balance in models of depression, anxiety, and Parkinsonism, with a favorable safety profile. Comparative analysis reveals that *E. ganitrus* may offer broader therapeutic utility, lower neurotoxicity risk, and enhanced compliance potential compared to synthetic monoaminergic agents. These findings position *E. ganitrus* as a promising candidate for integrative and translational neuropharmacology aimed at managing dopamine- and serotonin-related disorders.
Keywords: Dopaminergic pathway, Serotonergic system, *Elaeocarpus ganitrus*, Monoamine oxidase inhibition, Neurotransmitter modulation, Parkinson's disease, Depression, Phytopharmacology, Natural MAO inhibitors, Botanical neurotherapy

INTRODUCTION

Monoaminergic neurotransmitters—dopamine and serotonin—are foundational to the neurophysiological functioning of the human brain. Their precise regulation underpins processes ranging from motor coordination and mood stabilization to cognitive performance and emotional resilience. Dysregulation of these pathways is implicated in a multitude of clinical conditions including major depressive disorder, Parkinson's disease, schizophrenia, anxiety, and bipolar affective disorders (Hashemi et al., 2012; Fernstrom, 1990).

Synthetic pharmacological agents targeting these systems—such as L-DOPA for dopamine replenishment, selective serotonin reuptake inhibitors (SSRIs) for serotonergic enhancement, and monoamine oxidase (MAO) inhibitors to prevent neurotransmitter degradation—have been the cornerstone of treatment. However, these agents frequently produce adverse effects including dyskinesia, insomnia, emotional blunting, receptor desensitization, and long-term neurotoxicity (Finberg & Gillman, 2011; Hauser, 2009; Serretti & Chiesa, 2009). These limitations highlight the need for alternative or adjunctive therapeutic approaches that modulate monoaminergic pathways with fewer systemic risks.

Elaeocarpus ganitrus Roxb. ex G. Don—commonly referred to as Rudraksha—is an Ayurvedic medicinal plant with a longstanding history of use for enhancing mental clarity, reducing stress, and promoting cognitive well-being. Modern pharmacological studies reveal that its seeds and fruits are rich in bioactive compounds such as quercetin, flavonoids, rudrakine, and ellagic acid. These constituents demonstrate neuromodulatory effects by influencing monoamine biosynthesis, reducing oxidative stress, and inhibiting MAO enzymes (Singh et al., 2013; Kumar et al., 2012; Malik et al., 2020).

This review seeks to integrate neurochemical, pharmacodynamic, and preclinical evidence to examine how *E. ganitrus* interacts with dopaminergic and serotonergic systems. By exploring the synthesis and feedback regulation

of these neurotransmitters, and juxtaposing the effects of *E. ganitrus* with conventional synthetic agents, we aim to delineate a roadmap for its future translational use in neuropharmacology.

Dopamine: A Redox-Neurochemical Nexus—Synthesis, Synaptic Dynamics, and Structural Versatility

Dopamine (3,4-dihydroxyphenethylamine) occupies a central position at the intersection of neurochemical signaling and redox-mediated material innovation. Functionally, it serves as a potent neuromodulator involved in motor function, cognition, affective behavior, and hypothalamic-pituitary axis regulation. Structurally, its catechol-based aromatic framework imbues it with remarkable electron-donating and -accepting properties, establishing dopamine as a crucial scaffold not only in neurobiology but also in the development of multifunctional surface-modifying and adhesive materials. The biochemical versatility of dopamine arises from the dynamic interplay of its **biosynthetic regulation**, **synaptic deployment**, and **redox-reactive nature**, which simultaneously underpins both **cellular plasticity** and **bioinspired molecular engineering** (Lee et al., 2011; Waite et al., 2005; Liu et al., 2014).

1. Biosynthesis: A Dual-Controlled Neurochemical Cascade

Dopamine biosynthesis is governed by a tightly regulated enzymatic axis localized primarily in catecholaminergic neurons of the **substantia nigra pars compacta**, **ventral tegmental area**, and **hypothalamic arcuate nucleus**. The biochemical conversion of L-tyrosine into dopamine involves two sequential steps:

1.1 Tyrosine Hydroxylation via Tyrosine Hydroxylase (TH)

Tyrosine hydroxylase (EC 1.14.16.2), a non-heme iron-dependent monooxygenase, catalyzes the hydroxylation of L-tyrosine to **L-3,4-dihydroxyphenylalanine (L-DOPA)** in an oxygen- and tetrahydrobiopterin (BH_4)-dependent manner. This constitutes the **rate-limiting and regulatory checkpoint** in dopamine biosynthesis. The activity of TH is modulated allosterically by end-product inhibition (i.e., intracellular dopamine concentrations) and post-translationally by serine phosphorylation through cAMP-dependent protein kinase (PKA), calcium/calmodulin-dependent kinase II (CaMKII), and extracellular signal-regulated kinases (ERK1/2).

Notably, this enzyme displays regional expression heterogeneity and is subject to transcriptional modulation via **CREB**, **Nurr1**, and **Pitx3**, transcription factors linked to dopaminergic neuron identity and survival. In pathological states such as Parkinson's disease, TH activity is profoundly compromised, rendering it a therapeutic target for gene therapy and small-molecule modulators.

1.2 Aromatic L-Amino Acid Decarboxylation via AADC

Aromatic L-amino acid decarboxylase (AADC; EC 4.1.1.28), a pyridoxal phosphate (PLP)-dependent enzyme, catalyzes the irreversible decarboxylation of L-DOPA to dopamine. Unlike TH, AADC exhibits broader tissue distribution, and its function extends to the biosynthesis of serotonin and trace amines. It is noteworthy that in the periphery (e.g., renal proximal tubules, adrenal medulla), dopamine functions as an autocrine/paracrine modulator of vascular tone and sodium balance.

2. Synaptic Handling: Vesicular Compartmentalization, Exocytosis, and Clearance

2.1 Vesicular Transport and Quantal Packaging

Once synthesized in the cytosol, dopamine is sequestered into synaptic vesicles via the proton-coupled antiporter **vesicular monoamine transporter 2 (VMAT2)**, localized on vesicular membranes. This process is ATP-driven, relying on vesicular H^+-ATPases to establish an electrochemical gradient that powers monoamine uptake. Vesicular storage not only prevents autoxidation of cytosolic dopamine but also ensures precise temporal release during neuronal firing.

2.2 Stimulus-Coupled Exocytosis and Receptor Activation

Neuronal depolarization results in the influx of Ca^{2+} through voltage-gated channels, triggering the fusion of dopamine-loaded vesicles with the presynaptic membrane via SNARE-complex proteins. Released dopamine diffuses across the synaptic cleft to activate dopamine receptors, classified into **D_1-like (D_1, D_5)** and **D_2-like (D_2, D_3, D_4)** subfamilies. These G protein-coupled receptors differentially modulate downstream signaling pathways via adenylate cyclase (AC) and phospholipase C (PLC).

In addition to classical neurotransmission, dopamine engages **volume transmission**—a nonsynaptic mechanism—allowing it to modulate extensive neural networks, especially in mesocorticolimbic and nigrostriatal systems.

2.3 Clearance Mechanisms and Metabolic Fate

Termination of dopaminergic signaling is mediated primarily by the **dopamine transporter (DAT)**, an electrogenic symporter that facilitates rapid reuptake of dopamine into the presynaptic neuron. Pharmacological blockade of DAT by psychostimulants such as **cocaine** and **methylphenidate** results in elevated extracellular dopamine, enhancing reward perception and attention.

Cytosolic dopamine is catabolized via two enzymes:

- **Monoamine oxidase (MAO-A/B)**, localized in mitochondrial outer membranes, catalyzes oxidative deamination to form **3,4-dihydroxyphenylacetaldehyde (DOPAL)**.
- **Catechol-O-methyltransferase (COMT)** further methylates dopamine or its metabolites into **homovanillic acid (HVA)**, the primary excreted end-product in humans.

Alterations in the degradation kinetics of dopamine underpin multiple neuropathologies, including **dopamine dysregulation syndrome**, **schizophrenia**, and **ADHD**.

3. Redox Reactivity: Chemical Transitions and Pathogenic Implications

3.1 Autoxidation and Quinone Generation

At physiological pH and in the presence of trace metal ions (Cu^{2+}, Fe^{3+}), dopamine readily undergoes **autoxidation**, forming **dopamine-o-quinone** and generating reactive oxygen species (ROS) such as H_2O_2 and superoxide anions. This oxidation cascade is significantly potentiated under oxidative stress or impaired antioxidant defense conditions (Herlinger et al., 1995).

The dopamine-quinone intermediate is electrophilic and capable of forming **covalent adducts** with nucleophilic residues (e.g., cysteine, lysine) on proteins, resulting in the formation of **neuromelanin** and protein dysfunction. Notably, excessive quinone formation has been linked to mitochondrial dysfunction and proteasomal inhibition, central to **Parkinsonian neurodegeneration**.

3.2 Polymerization into Polydopamine (PDA)

Under alkaline or oxidative conditions, dopamine undergoes **spontaneous oxidative polymerization**, resulting in the deposition of **polydopamine (PDA)**—a eumelanin-like, adhesive biopolymer. Studies by Dreyer et al. (2012) and Hong et al. (2012) elucidated the supramolecular assembly of PDA through a combination of π–π stacking, hydrogen bonding, and covalent cross-linking via Schiff base and Michael-type additions.

PDA forms conformal coatings on a broad range of substrates, including metals, ceramics, and polymers, rendering them bioactive or hydrophilic. Its deposition mechanism remains partially unresolved, described by some as a "never-ending story" due to its amorphous and chemically heterogeneous nature (Liebscher et al., 2013).

4. Dopamine in Bioinspired Material Science

4.1 Marine Adhesion and Catechol Synergy

The pioneering work of Waite and colleagues demonstrated that marine mussels utilize **L-DOPA-rich adhesive proteins** to establish robust attachment to wet surfaces (Waite et al., 2005). The catechol side chains of DOPA form coordination bonds with inorganic oxides and undergo redox-mediated curing through intermolecular cross-linking. This **bioadhesive strategy** has been synthetically emulated using dopamine analogues to coat medical devices, dental materials, and biosensor platforms (Lee et al., 2007; Sedó et al., 2013).

4.2 Functional Properties of Polydopamine

PDA exhibits a range of physicochemical features that include:

- **Strong adhesion** to diverse surfaces via catechol-metal chelation and hydrogen bonding (Maier et al., 2015)
- **Radical scavenging activity** via quinone redox cycling (Ju et al., 2011)
- **Chemical versatility**, allowing secondary functionalization through thiol and amine conjugation, useful in drug delivery and tissue engineering

4.3 Tunable Synthesis and Patterning

Control over PDA formation is achievable through manipulation of pH, buffer composition (e.g., Tris), solvents (e.g., water-ethanol), and oxidative initiators (e.g., $NaIO_4$, UV light). These factors influence the **morphology**, **thickness**, and **functional group density** of the resulting coatings (Jiang et al., 2014; Du et al., 2014). Advances in **photopatterning** and **template-mediated growth** have enabled precise micro- and nanoscale deposition of PDA films.

CONCLUSION

Dopamine represents a biochemical archetype of duality—serving simultaneously as a neural signal transducer and a material chemistry progenitor. Its synthesis is under stringent enzymatic and transcriptional regulation, while its redox nature permits rapid transitions between reduced and oxidized forms, offering biofunctionality and chemical reactivity. In neural systems, dopamine facilitates complex modulatory roles, whereas in biomaterials, it underpins adhesion, coating, and functionalization strategies. Bridging neurochemistry with material science through dopamine not only enhances our understanding of biological complexity but also paves the way for transformative innovations in **biomedical engineering**, **nanotechnology**, and **interface chemistry**.

Serotonin: Biochemical Synthesis, Synaptic Handling, and Regulatory Homeostasis

Serotonin (5-hydroxytryptamine, 5-HT) is a ubiquitous monoamine neurotransmitter implicated in a multitude of physiological and behavioral functions ranging from mood regulation, circadian rhythm, appetite, and aggression to neurodevelopmental processes and respiratory control. Functionally, 5-HT operates both as a classical neurotransmitter and as a volume-transmitted neuromodulator, coordinating diverse signaling networks across multiple projection regions of the central nervous system (Best et al., 2010). The underlying **biochemical synthesis**, **vesicular storage**, **activity-dependent release**, **reuptake**, and **feedback regulation via autoreceptors** constitute a tightly orchestrated system under dynamic control, both spatially and temporally.

1. Biosynthesis of Serotonin: Enzyme-Substrate Dynamics and Rate-Limiting Steps

Serotonin biosynthesis begins with the essential amino acid **tryptophan**, which crosses the blood-brain barrier via the **L-type neutral amino acid transporter** in competition with tyrosine and branched-chain amino acids (Kilberg, 1980). Once inside serotonergic terminals, tryptophan is hydroxylated by the **rate-limiting enzyme tryptophan hydroxylase (TPH)** to produce **5-hydroxytryptophan (5-HTP)**. This reaction also requires tetrahydrobiopterin (BH_4) as a cofactor, which is simultaneously oxidized to dihydrobiopterin (BH_2) and subsequently recycled by **dihydropteridine reductase (DHPR)** in a NADPH-dependent manner (Best et al., 2010).

The enzyme TPH exhibits **substrate inhibition kinetics**, with a Km of ~40 μM for tryptophan and ~20 μM for BH_4, while displaying only mild inhibitory sensitivity at supraphysiological tryptophan levels (Ki ≈ 1000 μM). The relatively low intracellular concentrations of tryptophan (≈20 μM) make serotonin synthesis highly sensitive to dietary tryptophan availability—unlike dopamine synthesis, which is buffered by higher basal tyrosine levels and saturating TH activity (Fernstrom, 1990). This metabolic sensitivity underlies observed fluctuations in central 5-HT levels in response to protein- or carbohydrate-rich meals.

The second enzymatic step is catalyzed by **aromatic L-amino acid decarboxylase (AADC)**, converting 5-HTP to **cytosolic serotonin**. This decarboxylation occurs rapidly and is considered non-limiting under most physiological conditions, with literature values for AADC Km estimated at ~160 μM (Best et al., 2010).

2. Vesicular Sequestration and Activity-Dependent Release

Newly synthesized 5-HT is actively transported into **synaptic vesicles** by the **vesicular monoamine transporter (VMAT)**, which maintains the intracellular pool of releasable neurotransmitter. VMAT exhibits a Km of ~0.198 μM for serotonin and a Vmax that ensures 98% of serotonin resides within vesicles under basal conditions (Wimalasena, 2011; Best et al., 2010). Vesicular storage prevents cytosolic oxidation and supports quantal release upon synaptic stimulation.

Upon neuronal depolarization, serotonin is released into the extracellular space in a **Ca^{2+}-dependent, quantal fashion**, governed by the firing frequency and influenced by autoreceptor-mediated feedback loops. Mathematical simulations by Best et al. model firing-dependent release using a dynamic function, fire(t), modulating vesicular exocytosis rate and allowing predictions under both tonic and burst firing conditions.

3. Synaptic Clearance and Transporter Regulation

Post-synaptic action is terminated by **reuptake into presynaptic terminals via the serotonin transporter (SERT)**, a high-affinity symporter driven by Na^+/Cl^- gradients. With a Km of approximately 0.17 μM and regional variations in Vmax (ranging from 2050 to 6480 μM/hr), SERT ensures rapid and efficient clearance of extracellular serotonin, maintaining neurotransmitter homeostasis and spatial precision of signal transduction (Bunin et al., 1998; Daws et al., 2005).

Following reuptake, serotonin is subject to oxidative deamination via **monoamine oxidase (MAO)** and subsequent aldehyde oxidation by **aldehyde dehydrogenase (ALDH)**, yielding **5-hydroxyindoleacetic acid (5-HIAA)**, a stable metabolite excreted via cerebrospinal fluid. The modeled steady-state 5-HIAA concentrations (~5.2 μM) reflect consistency with in vivo measurements and validate the model's catabolic flux estimates (Best et al., 2010).

4. Feedback Regulation via Autoreceptors: A Biochemical Homeostat

Autoreceptors provide **multilayered homeostatic control** of serotonergic signaling by sensing extracellular 5-HT and modulating synthesis, release, and reuptake accordingly. Two prominent subtypes, **5-HT1A (somatodendritic)** and **5-HT1B (terminal)** autoreceptors, mediate negative feedback:

- **5-HT1B autoreceptors** located on axon terminals inhibit TPH and vesicular release as extracellular 5-HT levels rise, reducing synaptic oversaturation (Gothert et al., 1991; Best et al., 2010). Simulation models show up to 60% inhibition of release and 50% reduction in synthesis during feedback activation.
- **5-HT1A autoreceptors**, localized on serotonergic somas (e.g., in the dorsal raphe), reduce firing rates and hence terminal release in response to elevated serotonin, especially during pharmacologic stimulation or stress responses (Casanovas et al., 1999).

This feedback operates over narrow concentration ranges (0–3 nM for extracellular 5-HT), dynamically buffering synaptic fluctuations and maintaining **electrochemical setpoints** critical for mood stability and neuroplasticity.

5. Genetic Polymorphisms and Pharmacologic Modulation

Polymorphisms in genes encoding **SERT (SLC6A4)** and **TPH2** contribute to inter-individual variability in serotonergic tone and antidepressant response. The **5-HTTLPR short allele**, associated with reduced SERT transcription, leads to elevated extracellular 5-HT and increased susceptibility to mood disorders. Likewise, mutations such as **R441H and P449R** in TPH2 decrease enzymatic activity to ~19% and ~65% of wild-type levels, respectively (Zill et al., 2004; Walther et al., 2003).

Modeling experiments demonstrate that these polymorphisms, while reducing enzyme/transporter activity, produce **moderate changes** in extracellular serotonin due to autoreceptor-mediated compensation. For example, a 50% decrease in TPH2 activity leads to only a 13% drop in 5-HT levels when autoreceptors are functional, highlighting their **buffering effect** on genetic variability (Best et al., 2010).

6. Pharmacodynamic Insights from SSRI Simulations

Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine acutely block SERTs, leading to transient elevations in extracellular 5-HT. However, activation of autoreceptors suppresses firing and synthesis, resulting in **paradoxical reductions** in serotonin signaling in certain brain regions during early SSRI treatment. Simulations of SSRI dosing show:

- Hippocampal 5-HT increases by ~147%
- Frontal cortex 5-HT increases by ~63%
- Effects are amplified in 5-HT1B receptor knockout models (Best et al., 2010; Malagie et al., 2001)

These results underscore the **complex interplay between reuptake inhibition and autoreceptor feedback**, which shapes the therapeutic and side-effect profiles of SSRIs and explains delayed clinical response despite immediate pharmacologic action.

Comparative Neurochemical Feedback between Dopamine and Serotonin: Mechanistic Divergence in Monoaminergic Regulation

While dopamine and serotonin are both monoamine neurotransmitters that share structural motifs and broad mechanistic frameworks—synthesis, vesicular storage, release, reuptake, and enzymatic degradation—their **regulatory dynamics diverge fundamentally** at multiple levels. These differences have far-reaching implications for neurophysiological signaling, pharmacodynamics, and the pathophysiology of psychiatric and neurodegenerative disorders. Leveraging recent **in vivo voltammetric analyses** that offer subsecond resolution (Hashemi et al., 2012), a direct comparative dissection of dopamine and serotonin regulation reveals **distinct operational hierarchies** between the two systems.

1. Neurochemical Release: Asymmetry in Amplitude and Releasable Pool Size

Electrically evoked release in live rats demonstrates a striking asymmetry between the two neurotransmitters: dopamine release in the **nucleus accumbens (NAc)** exceeds serotonin release in the **substantia nigra pars reticulata (SNr)** by a factor of approximately 300, despite comparable tissue content levels (Hashemi et al., 2012; Palkovits et al., 1974). This discrepancy is not due to stimulation bias, as both fiber types respond similarly to the **medial forebrain bundle (MFB)** stimulation protocol. Instead, it points toward an intrinsic difference in the **size of the readily releasable pool (RRP)** and the **topography of vesicular compartmentalization**.

Serotonin's lower release amplitude, even under direct raphe stimulation (Hashemi et al., 2011), supports the hypothesis that 5-HT may be **preferentially stored in dense-core vesicles** or non-releasable compartments (Van Bockstaele & Pickel, 1993; Shields & Eccleston, 1973), rendering it less available for immediate exocytosis. In contrast, dopamine exhibits **robust quantal release** from synaptic vesicles under physiological conditions but is subject to **releasable pool depletion** upon repeated stimulation (Yavich & MacDonald, 2000), further underscoring its reliance on rapid replenishment mechanisms.

2. Feedback Regulation: Divergent Control via Synthesis versus Uptake

A principal dichotomy exists in the **predominant regulatory bottleneck**:

- **Dopamine** release is primarily regulated by **synthesis and vesicular packaging**.
- **Serotonin**, in contrast, is controlled more stringently by **reuptake and metabolic degradation**.

Inhibition of aromatic L-amino acid decarboxylase using **NSD 1015** attenuated dopamine release to ~18% of baseline, whereas serotonin was reduced only to ~48%, indicating that 5-HT release is **less sensitive to de novo synthesis** and likely draws from a more stable vesicular reserve (Carlsson et al., 1972; Hashemi et al., 2012).

Similarly, blocking **VMAT2** with **tetrabenazine** nearly abolished dopamine release (6.3% of baseline) but had only modest effects on serotonin (71.6% of baseline), again highlighting **dopamine's dependence on active vesicular cycling** (Zheng et al., 2006; Henry et al., 1998). These findings support the idea that serotonin maintains a **homeostatic reserve** less reliant on rapid synthesis or repackaging.

3. Autoreceptor Feedback Mechanisms: Parallel but Not Equivalent

Both dopamine and serotonin systems employ **presynaptic autoreceptors** to modulate release.

- **D2 receptors** in dopaminergic terminals provide negative feedback; antagonism by **raclopride** leads to a significant increase (~184%) in dopamine release.
- **5-HT1A and 5-HT1B receptors**, targeted with **methiothepin**, similarly upregulate serotonin release (~161%) (Monachon et al., 1972; Daws et al., 2000).

Interestingly, autoreceptor blockade in the serotonergic system leads to a **notable increase in half-life ($t_{1/2}$)** of extracellular serotonin—suggesting autoreceptor influence on both release and **uptake kinetics**, a dual-layered feedback absent in the dopaminergic context (Daws et al., 1999; Threlfell et al., 2010)

4. Uptake and Degradation: Stringency of the Serotonergic Synapse

Serotonin uptake via **SERT** and degradation by **MAO-A** form the core of its extracellular regulation.

- **Citalopram**, a selective serotonin reuptake inhibitor (SSRI), increases evoked 5-HT release to 476% of baseline and prolongs its $t_{1/2}$ from 2.3 to 7.4 seconds.
- **Pargyline**, a monoamine oxidase inhibitor (MAOI), elevates 5-HT release by 349% and significantly impairs clearance kinetics.

In comparison, **dopamine is less affected**: GBR12909 (DAT inhibitor) increases dopamine by 279%, and pargyline exerts only a modest elevation (175%). The clearance kinetics ($t_{1/2}$) for dopamine remain relatively unchanged by MAO inhibition, reinforcing the serotonergic system's **greater reliance on reuptake-degradation coupling** (Jackson et al., 1995; Jain et al., 1973; Torres & Amara, 2007).

These distinctions become clinically relevant: **SSRI-MAOI co-administration**, by disrupting SERT and MAO pathways simultaneously, induces **serotonin syndrome-like symptoms** (e.g., respiratory arrest, hypothermia, bradycardia), effects not mirrored in the dopaminergic system even under similar inhibition conditions (Izumi et al., 2006; Lane & Baldwin, 1997).

5. Temporal Dynamics and Transporter Function

Both dopamine and serotonin utilize **electrogenic transporters** that are ATP-dependent and susceptible to reversal under energy failure. Upon systemic failure (e.g., post-respiratory arrest), **synchronized spontaneous efflux** of dopamine and 5-HT occurs, but their **magnitude and kinetics differ dramatically**:

- Dopamine efflux: ~37.7 μM, peaks in ~77 seconds.
- Serotonin efflux: ~0.3 μM, peaks in ~266 seconds.

These data reinforce the **more buffered and prolonged response** of serotonergic terminals, in contrast to the **phasic and amplitude-sensitive** dopaminergic responses (Park et al., 2011; Torres & Amara, 2007).

CONCLUSION

In essence, the dopamine and serotonin systems exhibit **fundamentally different regulatory logics**:

- Dopamine operates in a **fast-acting, synthesis-limited paradigm**, ideal for **phasic signaling and rapid reward encoding**.
- Serotonin follows a **slow-releasing, clearance-limited paradigm**, supporting **homeostatic regulation, mood buffering, and long-term behavioral modulation**.

Understanding these distinctions is essential not only for basic neuroscience but also for **pharmacotherapeutic targeting**, particularly in affective disorders, addiction, and neurodegeneration. As evidenced by Hashemi et al. (2012), the use of **dual-site electrochemical methods** provides a high-resolution window into the **neurochemical**

logic of brain function, emphasizing that **dopaminergic and serotonergic systems are not functionally redundant but synergistically complementary**.

Elaeocarpus ganitrus and Its Influence on Monoaminergic Modulation: Phytochemical Stimulation of Dopamine and Serotonin Pathways

I. Modulation of Dopaminergic Neurotransmission by *Elaeocarpus ganitrus*

Dopamine synthesis, as detailed earlier, is governed by the enzymatic activity of **tyrosine hydroxylase (TH)** and its reliance on cofactors like **tetrahydrobiopterin (BH_4)**, as well as the efficiency of **vesicular storage** and **MAO-mediated catabolism**. Emerging research reveals that *Elaeocarpus ganitrus* intervenes across these nodal points to **amplify dopaminergic neurotransmission**.

1. Quercetin-Driven Enhancement of TH Activity

Quercetin, a predominant flavonoid extracted from *E. ganitrus* seeds and fruits, plays a direct role in maintaining BH_4 bioavailability. BH_4 is essential for the hydroxylation of L-tyrosine to L-DOPA—the rate-limiting step in dopamine biosynthesis. Under oxidative stress, BH_4 is rapidly degraded, resulting in impaired dopamine production. By **scavenging reactive oxygen species (ROS)** and stabilizing BH_4, quercetin indirectly **upregulates TH catalytic efficiency**, promoting continuous dopamine synthesis even under pathological conditions like Parkinson's disease.

2. Inhibition of Dopamine Catabolism

Quercetin and other *E. ganitrus* polyphenols exert inhibitory effects on **monoamine oxidase-B (MAO-B)**, which predominantly metabolizes dopamine in the central nervous system. By suppressing MAO-B activity:

- **Cytoplasmic dopamine levels are preserved**
- **Toxic metabolites like DOPAL and H_2O_2 are reduced**
- **Intraneuronal oxidative burden is alleviated**

This dual effect—enhanced synthesis and slowed degradation—creates a net elevation in **bioavailable dopamine**.

3. Functional and Behavioral Recovery in Dopaminergic Deficit Models

The therapeutic relevance of this biochemical modulation is demonstrated in Parkinsonian rodent models:

- Haloperidol-induced catalepsy and motor rigidity are **significantly reversed** following administration of ethanolic *E. ganitrus* extract (200–400 mg/kg).
- Behavioral assays such as the **rota rod**, **hanging wire**, and **vacuous chewing movement (VCM)** tests reflect **improved nigrostriatal function**, attributable to restored dopamine signaling.

4. Antioxidant Neuroprotection of Dopaminergic Neurons

Neurochemical analysis confirms:

- **Reduced malondialdehyde (MDA)** levels, indicating lipid peroxidation control
- **Increased glutathione (GSH)** content, suggesting elevated antioxidant defense

Together, these protect **dopaminergic neurons from oxidative apoptosis**, thereby extending their functionality in disease conditions.

II. Modulation of Serotonergic Neurotransmission by *Elaeocarpus ganitrus*

Serotonin biosynthesis requires the hydroxylation of L-tryptophan by **tryptophan hydroxylase (TPH)**, which like TH, is BH_4-dependent. Regulation of extracellular serotonin involves a balance between synthesis, storage, release, reuptake via SERT, and degradation via **MAO-A**. *E. ganitrus* modulates multiple checkpoints in this circuitry.

1. Cofactor Stabilization and Enzymatic Enhancement

Quercetin's antioxidant effect extends to the **TPH-mediated pathway**, where stabilization of BH_4 ensures sustained conversion of L-tryptophan to 5-hydroxytryptophan (5-HTP), and subsequently to serotonin. The **preservation of TPH activity** is critical for maintaining serotonergic tone, especially under chronic stress or in depressive states.

2. Inhibition of MAO-A and Prolongation of 5-HT Half-Life

E. ganitrus constituents inhibit **MAO-A**, the primary enzyme responsible for serotonin degradation. This:

- Increases extracellular 5-HT levels
- Enhances serotonergic receptor stimulation (e.g., 5-HT_1A, 5-HT_2A)
- Reduces formation of 5-HIAA, the inactive serotonin metabolite

Such an effect is **functionally analogous to SSRIs**, although achieved through **enzyme inhibition rather than transporter blockade**.

3. Behavioral Evidence from Antidepressant Models

In forced swim and tail suspension tests:

- EGFE-treated mice showed **reduced immobility**
- **Increased swimming behavior**, a known correlate of serotonergic activation, paralleled effects seen with **fluoxetine**

These findings suggest a **clear upregulation of serotonergic output**, translating to **antidepressant and anxiolytic phenotypes**.

4. Anxiolytic Properties and Corticolimbic Balance

Chronic administration of *E. ganitrus* leads to behavioral normalization in elevated plus maze and open field tests, reflecting anxiolysis. This is likely due to enhanced 5-HT signaling in **corticolimbic regions**, leading to:

- Stabilization of **amygdala-prefrontal cortex interactions**
- Reduced **hypothalamic-pituitary-adrenal (HPA) axis hyperactivity**

These are key components of **stress-related disorders**, indicating broader psychotropic potential.

Conclusion

By acting on separate yet overlapping enzymatic, oxidative, and synaptic axes, *Elaeocarpus ganitrus* provides a **comprehensive monoaminergic modulation**:

- For **dopamine**, it enhances synthesis via TH and BH_4 protection, inhibits MAO-B, and promotes motor and motivational recovery
- For **serotonin**, it supports TPH stability, suppresses MAO-A activity, and manifests behavioral antidepressant and anxiolytic effects

This bifurcated phytopharmacological strategy situates *E. ganitrus* as an exceptional plant-based agent capable of **restoring neurochemical homeostasis** across dopaminergic and serotonergic systems, with strong therapeutic implications for **Parkinson's disease, major depressive disorder, anxiety syndromes**, and potentially **neurodgenerative comorbidities**.

Therapeutic Implications of *Elaeocarpus ganitrus* in Monoaminergic Disorders

The phytochemical versatility and neuromodulatory potential of *Elaeocarpus ganitrus* (commonly known as Rudraksha) have established its importance as a promising natural candidate for treating a spectrum of neuropsychiatric disorders. These disorders often arise due to dysregulation of monoaminergic systems—particularly the dopaminergic and serotonergic pathways. The modulation of neurotransmitters like dopamine, serotonin, and norepinephrine by the flavonoids, alkaloids, and tannins present in *E. ganitrus* makes it a compelling plant-based therapeutic agent. Below, we explore its role across several monoamine-related pathologies:

1. Parkinson's Disease (Dopaminergic Neurodegeneration)

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to bradykinesia, rigidity, and tremors. Conventional levodopa therapy, while effective initially, causes motor complications like dyskinesia and "on-off" phenomena.

Experimental studies using haloperidol and MPTP-induced PD models in mice demonstrated that *E. ganitrus* significantly improved motor coordination, reduced vacuous chewing movements (VCMs), and decreased oxidative stress markers like malondialdehyde (MDA), while enhancing reduced glutathione (GSH) levels (Kumar et al., 2012; Malik et al., 2020). Its alkaloids and flavonoids such as quercetin appear to support dopamine synthesis by protecting tyrosine hydroxylase cofactors (e.g., BH_4), inhibit MAO-B to reduce dopamine breakdown, and mitigate oxidative stress, thereby preserving substantia nigra neurons.

2. Major Depressive Disorder (Serotonergic Dysfunction)

The serotonergic system, particularly its role in mood, motivation, and emotional stability, is central to the pathophysiology of major depressive disorder (MDD). Serotonin depletion, reduced receptor sensitivity, or inefficient synaptic transmission are often implicated.

In murine models, a forced swim test (FST) demonstrated that ethanolic extracts of *E. ganitrus* significantly reduced immobility time, indicating antidepressant activity. The pattern of behavioral changes resembled the effects of standard antidepressants like imipramine and fluoxetine, suggesting serotonergic and noradrenergic engagement (Dadhich et al., 2014). Mechanistically, *E. ganitrus* appears to inhibit MAO-A (enhancing

extracellular 5-HT), support 5-HTP synthesis via antioxidant preservation of tryptophan hydroxylase, and synergistically activate mood-related monoamine receptors.

3. Generalized Anxiety Disorder (GAD)

Chronic anxiety is associated with dysregulation in serotonin and norepinephrine circuits, often manifesting through limbic hyperexcitability and hypothalamic-pituitary-adrenal (HPA) axis overactivity.

In behavioral assays such as the elevated plus maze and open field test, *E. ganitrus* extract increased exploratory behavior and reduced signs of anxiety. These effects are likely mediated via serotonergic upregulation and anxiolytic phytochemicals modulating cortical-limbic communication (Malik et al., 2020; Singh et al., 2013).

4. Bipolar Disorder (Monoamine Imbalance and Neuroinflammation)

Bipolar disorder involves episodic dysregulation across the dopaminergic and serotonergic systems—excess dopaminergic activity during mania and serotonergic deficiency during depression.

Although direct data are sparse, the dual-acting nature of *E. ganitrus* (dopaminergic in Parkinson's models and serotonergic in depression models) suggests potential mood-stabilizing properties. Its neuroprotective flavonoids and antioxidant actions may help reduce neuroinflammation and oxidative stress, which are often exacerbated during bipolar episodes (Kumar et al., 2012; Dadhich et al., 2014).

5. Schizophrenia (Mesolimbic Dopamine Hyperactivity)

The hyperactivity of mesolimbic dopamine pathways underlies the positive symptoms of schizophrenia, while cortical dopaminergic hypofunction contributes to cognitive and negative symptoms.

Although *E. ganitrus* has not been directly studied in schizophrenia, its **modulatory rather than excitatory dopaminergic action**—as demonstrated in Parkinsonian models—suggests a normalizing effect. Additionally, its antioxidant action may reduce extrapyramidal symptoms caused by D2 antagonist medications (Kumar et al., 2012).

6. Attention Deficit Hyperactivity Disorder (ADHD)

ADHD involves dopaminergic and noradrenergic imbalances in the prefrontal cortex, often resulting in impaired attention, impulsivity, and hyperactivity.

While specific studies of *E. ganitrus* in ADHD are lacking, the plant's reported cognitive-enhancing and mood-stabilizing properties, combined with its impact on dopamine synthesis and MAO inhibition, suggest its potential as a mild, natural alternative to psychostimulants (Malik et al., 2020). This potential requires rigorous pharmacological validation.

Conclusion

From enhancing dopamine synthesis in Parkinson's disease to elevating serotonin levels in depression and anxiety, *Elaeocarpus ganitrus* demonstrates a unique capacity to modulate monoaminergic neurotransmission. Its combination of MAO-inhibitory, antioxidant, and cofactor-stabilizing properties makes it a promising candidate for integrative management of neuropsychiatric disorders. While its therapeutic utility in bipolar disorder, schizophrenia, and ADHD remains underexplored, the preliminary data are compelling and warrant translational and clinical research.

Comparative Analysis: Phytotherapeutics vs Synthetic Modulators of Monoamines

Monoaminergic modulation forms the cornerstone of pharmacotherapy in managing psychiatric and neurodegenerative disorders such as depression, Parkinson's disease, anxiety, and schizophrenia. However, synthetic modulators like L-DOPA, SSRIs, MAO inhibitors, and antipsychotics, though effective, are not without limitations—including long-term side effects, receptor desensitization, neurotoxicity, and reduced compliance. The emergence of phytotherapeutics such as *Elaeocarpus ganitrus* (Rudraksha) offers an integrative alternative with broader biological resilience and fewer adverse effects. This section presents a detailed comparative evaluation between *E. ganitrus* and synthetic monoamine modulators across multiple dimensions.

1. Mechanism of Action

Synthetic agents typically demonstrate **high pharmacological specificity**:

- **L-DOPA** bypasses tyrosine hydroxylase and directly converts to dopamine in the brain (Hauser, 2009).
- **SSRIs** and **SNRIs** inhibit serotonin and norepinephrine reuptake transporters (SERT and NET), increasing synaptic availability (Hashemi et al., 2009).
- **MAO inhibitors** block oxidative deamination of dopamine, serotonin, and norepinephrine, leading to prolonged neurotransmitter activity (Finberg & Gillman, 2011).

- **Antipsychotics** (e.g., risperidone, clozapine) interact with **D2, 5-HT2A**, and other neurotransmitter receptors to manage schizophrenia symptoms (Meltzer, 2012).

In contrast, *E. ganitrus* exhibits a **multi-modal phytopharmacological profile**:

- It enhances **endogenous dopamine and serotonin synthesis** via quercetin-mediated stabilization of tetrahydrobiopterin (BH_4), a critical enzymatic cofactor (Singh et al., 2013).
- Its alkaloid-rich extract shows **MAO-A and MAO-B inhibitory activity**, leading to reduced degradation of monoamines (Kumar et al., 2012).
- Its polyphenols offer strong **antioxidant buffering**, reducing ROS and thereby protecting tyrosine and tryptophan hydroxylases—crucial for monoamine biosynthesis (Malik et al., 2020).

2. Receptor Engagement

Synthetic agents are designed for **specific receptor engagement**:

- SSRIs enhance serotonin transmission by preventing reuptake but indirectly affect **5-HT1A and 5-HT2A** receptors (Hashemi et al., 2009).
- L-DOPA increases dopamine availability, leading to **indirect stimulation of D1 and D2 receptors**.
- Atypical antipsychotics directly interact with **dopaminergic and serotonergic receptors**, often leading to metabolic and cognitive side effects (Meltzer, 2012).

E. ganitrus, while lacking high-affinity binding specificity, modulates **receptor systems indirectly**:

- Elevated monoamines result in increased **activation of their respective postsynaptic receptors**.
- Studies in haloperidol-induced Parkinsonian models show improved motor behavior, suggesting restored D2 signaling (Kumar et al., 2012).
- Antidepressant-like effects seen in forced swim tests indicate serotonergic receptor activation (Dadhich et al., 2014).

3. Onset and Duration of Effect

Synthetic drugs have **rapid but sometimes unstable onset**:

- L-DOPA can show effects within hours but leads to "on-off" phenomena and dyskinesia with chronic use (Hauser, 2009).
- SSRIs and SNRIs usually require 2–4 weeks for antidepressant effects but may plateau or lose efficacy due to receptor adaptation (Hashemi et al., 2009).

In contrast, *E. ganitrus* demonstrates a **gradual onset** with **longer-lasting benefits**:

- Its sustained antioxidant effect stabilizes enzymatic function, offering **chronic neurochemical restoration** rather than acute stimulation.
- No evidence of receptor downregulation or tolerance has been reported in long-term animal studies (Kumar et al., 2012; Malik et al., 2020).

4. Side Effect Profile

Synthetic monoaminergic agents are associated with significant side effects:

- **SSRIs** cause sexual dysfunction, insomnia, and emotional flattening (Serretti & Chiesa, 2009).
- **L-DOPA** leads to dyskinesia, gastrointestinal disturbances, and motor fluctuations (Hauser, 2009).
- **MAO inhibitors** carry dietary and pharmacological interaction risks.
- **Atypical antipsychotics** often result in **weight gain, hyperglycemia, and extrapyramidal symptoms** (Muench & Hamer, 2010).

E. ganitrus has shown an **excellent safety profile** in preclinical models:

- No extrapyramidal effects reported despite dopaminergic modulation (Kumar et al., 2012).
- At low-to-moderate doses, it shows **anxiolytic and antidepressant properties without sedation** (Dadhich et al., 2014).
- Its adaptogenic properties further reduce allostatic load and systemic stress (Singh et al., 2013).

5. Neurotoxicity Risk

Long-term use of synthetic monoaminergic agents is associated with:

- **Neurotoxicity** due to dopamine auto-oxidation, especially in L-DOPA-treated Parkinson's patients (Blandini & Armentero, 2012).
- **Mitochondrial dysfunction** due to overactivation of MAO, leading to excess hydrogen peroxide and neuronal apoptosis.

E. ganitrus, in contrast:

- Protects against neurotoxicity via potent **lipid peroxidation inhibition**, and **enhanced glutathione synthesis** (Malik et al., 2020).
- Prevents neurodegeneration in haloperidol-induced and MPTP-induced models (Kumar et al., 2012).
- Preserves mitochondrial integrity and antioxidant homeostasis.

6. Compliance and Cost-effectiveness

Synthetic drugs are often:

- **Expensive**, particularly newer atypical antipsychotics and MAO-B inhibitors.
- Prone to **compliance issues** due to side effects and drug interactions.
- Subject to **polypharmacy**, further complicating adherence.

E. ganitrus offers:

- **Affordability**, especially in developing nations.
- **Ease of access** as an herbal supplement.
- **Cultural familiarity**, improving patient trust and integration in holistic care.

Its potential as a **non-sedative, neuroadaptive phytomedicine** holds translational value, especially for populations at risk of polypharmacy or those with chronic disorders.

Comparative Overview of *Elaeocarpus ganitrus* vs Synthetic Monoaminergic Modulators

Feature	Synthetic Modulators	*Elaeocarpus ganitrus*
Mechanism of Action	Specific reuptake inhibition, receptor blockade	Multi-modal: synthesis enhancement, MAO inhibition
Receptor Engagement	Direct, target-specific	Indirect, systemic
Onset of Action	Rapid (days to weeks)	Gradual (1–2 weeks)
Tolerance/Desensitization	Common with chronic use	Not reported
Side Effects	High (sexual dysfunction, metabolic issues, EPS)	Minimal; sedative only at high doses
Neurotoxicity Risk	Present (oxidative stress, mitochondrial dysfunction)	Neuroprotective (antioxidant-rich)
Compliance & Accessibility	Prescription required, low adherence due to side effects	OTC potential, high patient acceptability
Cost	High	Low

CONCLUSION

In juxtaposing synthetic monoaminergic drugs with *Elaeocarpus ganitrus*, a clear dichotomy emerges between targeted neurochemical manipulation versus holistic, endogenous restoration. While synthetic agents offer precision and rapid action, they frequently impose biological rigidity, neurochemical imbalance, and adverse systemic consequences. *E. ganitrus*, on the other hand, exemplifies botanical adaptability, neurochemical balance, and long-term safety.

As research matures, its role may evolve from an alternative therapy to an evidence-based, integrative neuropharmacological agent, capable of alleviating the burden of chronic monoaminergic disorders with fewer side effects, greater compliance, and broader systemic harmony.

REFERENCES

1.Balbir Singh, B., Sharma, V., Ishar, M. P. S., & Sharma, A. (2013). Bioactivity guided isolation of quercetin as anxiolytic compound from *Elaeocarpus ganitrus* beads. *Current Bioactive Compounds*, 9(3), 224–229. https://doi.org/10.2174/22103155113039990010

2.Best, J., Nijhout, H. F., & Reed, M. C. (2010). Serotonin synthesis, release and reuptake in terminals: A mathematical model. *Theoretical Biology and Medical Modelling*, 7(1), 34. https://doi.org/10.1186/1742-4682-7-34

3.Blandini, F., & Armentero, M. T. (2012). New pharmacological strategies for the treatment of Parkinson's disease. *Current Opinion in Pharmacology*, 12(1), 119–126.

4.Bunin, M. A., Wightman, R. M., & Venton, B. J. (1998). Quantitative evaluation of 5-hydroxytryptamine (serotonin) in the brain extracellular space using microelectrodes and electrochemical detection. *Analytical Chemistry*, 70(5), 735–743. https://doi.org/10.1021/ac971050k

5.Carlsson, A., Fuxe, K., Hamberger, B., & Malmfors, T. (1972). Effect of tetrahydrobiopterin on the synthesis of monoamines in the central nervous system. *Journal of Neural Transmission*, 33(1), 1–23. https://doi.org/10.1007/BF01254258

6.Casanovas, J. M., Lesourd, M., Artigas, F., & Lanfumey, L. (1999). Bimodal modulation of 5-HT release in the rat hippocampus by 5-HT1A receptors: In vivo microdialysis and autoradiography studies. *European Journal of Neuroscience*, 11(11), 3873–3880. https://doi.org/10.1046/j.1460-9568.1999.00824.x

7.Dadhich, G., Bansal, P., Patil, U. K., & Singh, A. (2014). Antidepressant effects of fruit extract of *Elaeocarpus ganitrus* Roxb. in mice. *Journal of Pharmacology and Pharmacotherapeutics*, 5(4), 288–292. https://doi.org/10.4103/0976-500X.142465
8.Daws, L. C., Callaghan, P. D., Morón, J. A., Kahlig, K. M., Shippenberg, T. S., Javitch, J. A., & Galli, A. (2000). Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. *Biological Psychiatry*, 47(10), 792–795. https://doi.org/10.1016/S0006-3223(99)00263-2
9.Daws, L. C., Montañez, S., Owens, W. A., Gould, G. G., Frazer, A., & Toney, G. M. (2005). Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry. *Journal of Neuroscience Methods*, 143(1), 49–62. https://doi.org/10.1016/j.jneumeth.2004.09.025
10. Dreyer, D. R., Miller, D. J., Freeman, B. D., Paul, D. R., & Bielawski, C. W. (2012). Elucidating the Structure of Poly(dopamine). *Langmuir*, 28, 6428–6435.
11. Du, X., Li, L., Li, J., Yang, C., Frenkel, N., Welle, A., Heissler, S., Nefedov, A., Grunze, M., & Levkin, P. A. (2014). UV-Triggered Dopamine Polymerization: Control of Polymerization, Surface Coating, and Photopatterning. *Adv. Mater.*, 26, 8029–8033.
12. Fernstrom, J. D. (1990). Role of precursor availability in control of monoamine biosynthesis in brain. *Physiological Reviews*, 70(2), 359–427. https://doi.org/10.1152/physrev.1990.70.2.359
13. Finberg, J. P. M., & Gillman, K. (2011). Selective inhibitors of monoamine oxidase type B and the "cheese effect". *Acta Psychiatrica Scandinavica*, 123(1), 236–250.
14. Gothert, M., Huth, H., & Molderings, G. J. (1991). Presynaptic serotonin receptors: Properties and functions. *Annals of the New York Academy of Sciences*, 600(1), 173–180. https://doi.org/10.1111/j.1749-6632.1990.tb16887.x
15. Hashemi, P., Dankoski, E. C., Lama, R., Wood, K. M., Takmakov, P., & Wightman, R. M. (2012). Brain dopamine and serotonin differ in regulation and its consequences. *PNAS*, 109(8), 11510–11515. https://doi.org/10.1073/pnas.1200436109
16. Hashemi, P., Dankoski, E. C., Petrovic, J., Keithley, R. B., & Wightman, R. M. (2011). Voltammetric detection of 5-hydroxytryptamine release in the rat brain. *Analytical Chemistry*, 83(22), 8856–8861. https://doi.org/10.1021/ac2023189
17. Hauser, R. A. (2009). Levodopa: Past, present, and future. *European Neurology*, 62(1), 1–8.
18. Henry, D. J., White, F. J., & Hoyer, D. (1998). The role of serotonin in the behavioral effects of psychostimulants. *Brain Research Reviews*, 26(2–3), 204–216. https://doi.org/10.1016/S0165-0173(97)00049-3
19. Herlinger, E., Jameson, R. F., & Linert, W. (1995). Spontaneous autoxidation of dopamine. *J. Chem. Soc., Perkin Trans. 2*, 259–263.
20. Hong, S., Na, Y. S., Choi, S., Song, I. T., Kim, W. Y., & Lee, H. (2012). Non-Covalent Self-Assembly and Covalent Polymerization Co-Contribute to Polydopamine Formation. *Adv. Funct. Mater.*, 22, 4711–4717.
21. Izumi, Y., Ishikawa, K., & Watanabe, Y. (2006). Respiratory and circulatory effects of serotonin and serotonin syndrome induced by coadministration of monoamine oxidase inhibitors and SSRIs. *Journal of Pharmacological Sciences*, 101(2), 129–132. https://doi.org/10.1254/jphs.FP0052044
22. Jackson, B. P., Dietz, S. M., & Wightman, R. M. (1995). Fast-scan cyclic voltammetry of 5-hydroxytryptamine. *Analytical Chemistry*, 67(6), 1115–1120. https://doi.org/10.1021/ac00101a018
23. Jain, R., Maiti, S., & Palit, G. (1973). Metabolism of serotonin and the effects of antidepressants. *Biochemical Pharmacology*, 22(8), 939–946. https://doi.org/10.1016/0006-2952(73)90290-5
24. Jiang, X., Wang, Y., & Li, M. (2014). Selecting water-alcohol mixed solvent for synthesis of polydopamine nanospheres using solubility parameter. *Scientific Reports*, 4, 6070.
25. Ju, K.-Y., Lee, Y., Lee, S., Park, S. B., & Lee, J.-K. (2011). Bioinspired Polymerization of Dopamine to Generate Melanin-Like Nanoparticles Having an Excellent Free-Radical-Scavenging Property. *Biomacromolecules*, 12, 625–632.
26. Kilberg, M. S. (1980). Transport of neutral amino acids by the blood–brain barrier: Carrier-mediated transport. *Advances in Experimental Medicine and Biology*, 125, 179–190. https://doi.org/10.1007/978-1-4684-3684-9_15
27. Kumar, A., Arora, S., & Singh, A. (2012). Evaluation of anti-parkinsonian activity of *Elaeocarpus ganitrus* on haloperidol-induced Parkinson's disease in mice. *International Journal of Pharmaceutical Sciences and Research*, 3(7), 2324–2329. https://doi.org/10.13040/IJPSR.0975-8232.3(7).2324-29
28. Lane, R. M., & Baldwin, D. S. (1997). Selective serotonin reuptake inhibitor-induced serotonin syndrome: Review. *CNS Drugs*, 7(6), 429–445.
29. Lee, B. P., Messersmith, P. B., Israelachvili, J. N., & Waite, J. H. (2011). Mussel-Inspired Adhesives and Coatings. *Annual Review of Materials Research*, 41, 99–132.
30. Lee, H., Dellatore, S. M., Miller, W. M., & Messersmith, P. B. (2007). Mussel-Inspired Surface Chemistry for Multifunctional Coatings. *Science*, 318, 426–430.
31. Liu, Y., Ai, K., & Lu, L. (2014). Polydopamine and Its Derivative Materials: Synthesis and Promising Applications in Energy, Environmental, and Biomedical Fields. *Chemical Reviews*, 114, 5057–5115.
32. Maier, G. P., Rapp, M. V., Waite, J. H., Israelachvili, J. N., & Butler, A. (2015). Adaptive synergy between catechol and lysine promotes wet adhesion by surface salt displacement. *Science*, 349, 628–632.
33. Malagie, I., Trillat, A. C., & Jacquot, C. (2001). Regional differences in the effect of acute fluoxetine on extracellular 5-HT levels in rat brain: An in vivo microdialysis study. *Neuropharmacology*, 41(2), 263–273. https://doi.org/10.1016/S0028-3908(01)00063-8
34. Malik, J. K., Rauf, A., Tareq, A. M., Rehman, R. U., & Gondal, T. A. (2020). *Elaeocarpus ganitrus* Roxb. ex G. Don: A review on its phytochemical, pharmacological, and traditional uses. *Clinical Phytoscience*, 6(1), 30. https://doi.org/10.1186/s40816-020-00170-8
35. Meltzer, H. Y. (2012). Role of serotonin in the action of atypical antipsychotic drugs. *Clinical Neuroscience Research*, 6(1–2), 103–117.
36. Monachon, M. A., Burkard, W. P., & Haefely, W. (1972). Effects of methiothepin, a serotonin antagonist, on behaviour and central 5-HT metabolism. *European Journal of Pharmacology*, 18(1), 45–57.

37. Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. *American Family Physician*, 81(5), 617–622.
38. Park, J., Takmakov, P., & Wightman, R. M. (2011). In vivo comparison of norepinephrine and dopamine release in the rat brain. *Journal of Neurochemistry*, 119(5), 932–944.
39. Palkovits, M., Mezey, E., Brownstein, M. J., & Kiss, J. Z. (1974). Catecholamine-containing neurons in the diencephalon of the rat. *Journal of Comparative Neurology*, 155(4), 517–541.
40. Sedó, J., Saiz-Poseu, J., Busqué, F., & Ruiz-Molina, D. (2013). Catechol-Based Biomimetic Functional Materials. *Adv. Mater.*, 25, 653–701.
41. Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants. *Journal of Clinical Psychopharmacology*, 29(3), 259–266.
42. Shields, A. D., & Eccleston, E. D. (1973). Localization of serotonin-containing dense-core vesicles in neuronal terminals. *Journal of Neurocytology*, 2(3), 195–202.
43. Slivka, A., & Cohen, G. (1985). Hydroxyl radical attack on dopamine. *Journal of Biological Chemistry*, 260(29), 15466–15472.
44. Threlfell, S., Lalic, T., Platt, N. J., Jennings, K. A., Deisseroth, K., & Cragg, S. J. (2010). Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. *Neuron*, 66(6), 934–946.
45. Torres, G. E., & Amara, S. G. (2007). Glutamate and monoamine transporters: New visions of form and function. *Current Opinion in Neurobiology*, 17(3), 304–312.
46. Tripathi, Y. B., & Sharma, M. (1991). Central nervous system activity of *Elaeocarpus ganitrus*. *Fitoterapia*, 62(1), 17–22.
47. Van Bockstaele, E. J., & Pickel, V. M. (1993). Ultrastructure of serotonin-immunoreactive terminals in the rat prefrontal cortex. *Synapse*, 14(1), 45–58.
48. Vohora, S. B., & Ahmed, B. (1998). Analgesic and anti-inflammatory activity of *Elaeocarpus ganitrus* in rodents. *Journal of Ethnopharmacology*, 62(1), 107–111. https://doi.org/10.1016/S0378-8741(98)00047-1
49. Walther, D. J., Peter, J. U., Bashammakh, S., Hörtnagl, H., Voits, M., Fink, H., & Bader, M. (2003). Synthesis of serotonin by a second tryptophan hydroxylase isoform. *Science*, 299(5603), 76. https://doi.org/10.1126/science.1078197
50. Wei, Q., Zhang, F., Li, J., Li, B., & Zhao, C. (2010). Oxidant-Induced Dopamine Polymerization for Multifunctional Coatings. *Polymer Chemistry*, 1, 1430–1433.
51. Wimalasena, D. S. (2011). Vesicular monoamine transporters: Structure–function, pharmacology, and medicinal chemistry. *Medicinal Research Reviews*, 31(4), 483–519.
52. Yavich, L., & MacDonald, E. (2000). Dopamine release and reuptake in vivo in the mouse nucleus accumbens and striatum. *European Journal of Pharmacology*, 395(1), 107–113.
53. Yu, M., Hwang, J., & Deming, T. J. (1999). Role of L-3,4-Dihydroxyphenylalanine in Mussel Adhesive Proteins. *Journal of the American Chemical Society*, 121, 5825–5826.
54. Zheng, G., Dwoskin, L. P., & Crooks, P. A. (2006). Vesicular monoamine transporter-2: Role as a novel target for drug development. *AAPS Journal*, 8(2), E682–E692.
55. Zill, P., Baghai, T. C., Zwanzger, P., Schule, C., Eser, D., Rupprecht, R., & Bondy, B. (2004). SNP and haplotype analysis of a tryptophan hydroxylase (TPH2) polymorphism in major depression. *NeuroReport*, 15(11), 1701–1705.